The results identify a novel activity of ARF, independent of its tumor suppressor activity, and raise the possibility that persistent overexpression of ARF could contribute to endogenous DNA damage in cancer cells by dysregulation of topo I. This evidence concerns the gene CDKN2A and cancer.